期刊
JOURNAL OF EXPERIMENTAL MEDICINE
卷 214, 期 1, 页码 27-37出版社
ROCKEFELLER UNIV PRESS
DOI: 10.1084/jem.20161274
关键词
-
资金
- National Institutes of Health [AI026918, AI030663, HL107202]
- Diabetes Endocrinology Research Center at the University of California, San Francisco [DK063720]
- Howard Hughes Medical Institute
- Sandler Asthma Basic Research Center at the University of California, San Francisco
- [DRG-2162-13]
Group 2 innate lymphoid cells (ILC2s) and type 2 helper T cells (Th2 cells) are the primary source of interleukin 5 (IL-5) and IL-13 during type 2 (allergic) inflammation in the lung. In Th2 cells, T cell receptor (TCR) signaling activates the transcription factors nuclear factor of activated T cells (NFAT), nuclear factor kappa B (NF-kappa B), and activator protein 1 (AP-1) to induce type 2 cytokines. ILC2s lack a TCR and respond instead to locally produced cytokines such as IL-33. Although IL-33 induces AP-1 and NF-kappa B, NFAT signaling has not been described in ILC2s. In this study, we report a nonredundant NFAT-dependent role for lipid-derived leukotrienes (LTs) in the activation of lung ILC2s. Using cytokine reporter and LT-deficient mice, we find that complete disruption of LT signaling markedly diminishes ILC2 activation and downstream responses during type 2 inflammation. Type 2 responses are equivalently attenuated in IL-33-and LT-deficient mice, and optimal ILC2 activation reflects potent synergy between these pathways. These findings expand our understanding of ILC2 regulation and may have important implications for the treatment of airways disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据